- Home
- GMAB vs ACM Comparison
GMAB vs ACM Comparison
Compare GMAB & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ACM
- Stock Information
- Founded
- GMAB 1999
- ACM 1980
- Country
- GMAB Denmark
- ACM United States
- Employees
- GMAB N/A
- ACM N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ACM Military/Government/Technical
- Sector
- GMAB Health Care
- ACM Consumer Discretionary
- Exchange
- GMAB Nasdaq
- ACM Nasdaq
- Market Cap
- GMAB 15.4B
- ACM 16.6B
- IPO Year
- GMAB N/A
- ACM 2007
- Fundamental
- Price
- GMAB $28.61
- ACM $127.64
- Analyst Decision
- GMAB Buy
- ACM Strong Buy
- Analyst Count
- GMAB 6
- ACM 10
- Target Price
- GMAB $37.60
- ACM $128.50
- AVG Volume (30 Days)
- GMAB 1.4M
- ACM 819.6K
- Earning Date
- GMAB 11-05-2025
- ACM 08-04-2025
- Dividend Yield
- GMAB N/A
- ACM 0.81%
- EPS Growth
- GMAB 77.72
- ACM 147.22
- EPS
- GMAB 21.62
- ACM 4.59
- Revenue
- GMAB $3,646,881,232.00
- ACM $16,074,699,000.00
- Revenue This Year
- GMAB $22.68
- ACM $2.09
- Revenue Next Year
- GMAB $15.85
- ACM $5.76
- P/E Ratio
- GMAB $1.32
- ACM $27.82
- Revenue Growth
- GMAB 32.97
- ACM 1.50
- 52 Week Low
- GMAB $17.24
- ACM $85.00
- 52 Week High
- GMAB $28.74
- ACM $128.04
- Technical
- Relative Strength Index (RSI)
- GMAB 81.36
- ACM 67.24
- Support Level
- GMAB $27.58
- ACM $123.89
- Resistance Level
- GMAB $27.61
- ACM $128.04
- Average True Range (ATR)
- GMAB 0.37
- ACM 2.20
- MACD
- GMAB 0.26
- ACM -0.08
- Stochastic Oscillator
- GMAB 97.02
- ACM 93.50
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.